Overview
- A University of Birmingham study published Monday used human blood‑derived microglia and living neurosurgical brain slices to test how the P2X7 receptor controls inflammation.
- The team showed that activating P2X7 with the chemical BzATP raised release of the pro‑inflammatory proteins IL‑1β and IL‑18 and that selective P2X7 antagonists sharply reduced that release.
- Blocking P2X7 also cut cytokine release in intact human brain tissue, implicating the inflammasome pathway (NLRP3 and caspase‑1) as the mechanism driving the response.
- Because brain‑penetrant P2X7 antagonists have already reached clinical testing, the authors say these drugs can be repurposed quickly and clinical trial protocols are now being developed.
- If trials confirm benefit and safety, patients with traumatic brain injury, Alzheimer’s, Parkinson’s and inflammation‑linked psychiatric disorders could see new targeted treatments that limit damaging neuroinflammation.